Balraj Singh, Ph.D.
Department of Breast Surgical Oncology, Division of Surgery
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Inflammatory Breast Cancer, breast cancer, triple-negative breast cancer, therapy-resistant cancer, tumor progression, metastasis, tumor heterogeneity, cancer metabolism, tumor adaptability, tumor evolution, metabolic adaptability, disseminated tumor cells, tumor cell quiescence, predictive assay development, cancer therapeutics.
Education & Training
Degree-Granting Education
| 1978 | Jawaharlal Nehru University, New Delhi, IND, PHD, Cell Biology |
| 1976 | Jawaharlal Nehru University, New Delhi, IND, MPhil, Life Sciences |
| 1974 | G.B. Pant University of Ag. & Tech, Pantnagar, IND, MS, Biochemistry |
| 1971 | G.B. Pant University of Ag. & Tech, Pantnagar, IND, BS, Chemistry, Physics, Mathematics |
Postgraduate Training
| 1981-1983 | Postdoctoral Fellow, Roche Institute of Molecular Biology, Nutley, NJ |
| 1979-1981 | Research Associate, Department of Microbiology and Immunology, Washington University School of Medicine, St. Louis, MO |
| 1978-1979 | Research Fellowship, School of Life Sciences, Jawaharlal Nehru University, New Delhi |
Selected Publications
Peer-Reviewed Articles
- Addanki S, Meas S, Sarli VN, Singh B, Lucci A. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers (Review). Int. J. Mol. Sci 23(14):7843, 2022. e-Pub 2022.
- Singh B, Sarli VN, Lucci A. Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor. Cancers 14(11):2631, 2022. e-Pub 2022.
- Singh B, Sarli VN, Lucci A. Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine. Oncotarget 12(7):626-637, 2021.
- Singh B, Sarli VN, Kinne HE, Shamsnia A, Lucci A. Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. Oncotarget 10(38):3681-3693, 2019.
- Singh B, Sarli VN, Washburn LJ, Raythatha MR, Lucci A. A usable model of “decathlon winner” cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence. Oncotarget 9(13):11071-11082, 2018. e-Pub 2018.
- Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS ONE 11(7):e0159072, 2016.
- Singh B, Shamsnia A, Raythatha MR, Milligan RD, Cady AM, Madan S, Lucci A. Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents. PLoS ONE 9(10):e109487, 2014.
- Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer H, Bedrosian I, Singh B, Lucci A. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer 118(2):342-348, 2012. e-Pub 2011.
- Singh B, Tai K, Madan S, Raythatha MR, Cady AM, Braunlin M, Iring LR, Bajaj A, Lucci A. Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS ONE 7(5):e3610, 2012.
- Singh B, Cook KR, Vincent L, Martin C, Lucci A. Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res 168(1):e39-49, 2011. e-Pub 2010.
- Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 116(14):3330-3337, 2010. PMID: 20564098.
- Singh B, Cook KR, Martin C, Huang EH, Mosalpuria K, Krishnamurthy S, Cristofanilli M, Lucci A. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis 27(4):233-240, 2010. e-Pub 2010. PMID: 20229045.
- Singh B, Irving LR, Tai K, Lucci A. Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res 164(2):235-243, 2010. e-Pub 2010.
- Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clin Cancer Res 15(21):6639-6648, 2009. e-Pub 2009. PMID: 19825949.
- Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117(1):61-68, 2009. e-Pub 2008. PMID: 18663571.
- Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2):231-6, 2009. e-Pub 2008. PMID: 19482312.
- Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 113(3):501-507, 2009. e-Pub 2009. PMID: 18327638.
- Pham CD, Vuyyuru VB, Yang Y, Bai W, Singh B. Evidence for an important role of serine 16 and its phosphorylation in the stabilization of c-Mos. Oncogene 18:4287-94, 1999. PMID: 10439036.
- Yang Y, Pham CD, Vuyyuru VB, Liu H, Arlinghaus RB, Singh B. Evidence of a functional interaction between serine 3 and serine 25 Mos phosphorylation sites. A dominant inhibitory role of serine 25 phosphorylation on Mos protein kinase. J Biol Chem 273:15946-53, 1998. PMID: 9632642.
- Singh B, Arlinghaus RB. Mos and the cell cycle. Prog Cell Cycle Res 3:251-9, 1997. PMID: 9552420.
- Yang Y, Herrmann CH, Arlinghaus RB, Singh B. Inhibition of v-Mos kinase activity by protein kinase A. Mol Cell Biol 16:800-9, 1996. PMID: 8622681.
- Pham CD, Arlinghaus RB, Zheng CF, Guan KL, Singh B. Characterization of MEK1 phosphorylation by the v-Mos protein. Oncogene 10:1683-8, 1995. PMID: 7731726.
- Hamelin R, Planchon P, Singh B, Arlinghaus RB. Inhibition of viral mos gene expression in transformed cells restricts cells cycle progression through G1 and G2 phases. Int J Oncology 1:513-523, 1992.
- Zhao X, Batten B, Singh B, Arlinghaus RB. Requirement of the c-Mos protein kinase for murine meiotic maturation. Oncogene 5:1727-1730, 1990.
- Singh B, Herzog NK, Liu J, Arlinghaus RB. p37mos encoded by the HT-1 strain of Moloney murine sarcoma virus has an associated protein kinase activity. Oncogene 3:79-85, 1988.
- Singh B, Wittenberg C, Hannink M, Reed SI, Donoghue DJ, Arlinghaus RB. The histidine-221 to tyrosine substitution in v-mos abolishes its biological function and its protein kinase activity. Virology 164:114-20, 1988. PMID: 2966489.
- Singh B, Wittenberg C, Reed SI, Arlinghaus RB. Moloney murine sarcoma virus encoded p37mos expressed in yeast has protein kinase activity. Virology 152:502-506, 1986.
- Singh B, Hannink M, Donoghue DJ, Arlinghaus RB. p37mos associated serine/threonine protein kinase activity correlates with the cellular transformation function of v-mos. J Virol 60:1148-1152, 1986.
- Roy MK, Singh B, Ray BK, Apirion D. Maturation of 5S rRNA: Ribonuclease E cleavages and their dependence on precursor sequences. Eur J Biochem 131:119-127, 1983.
- Ray BK, Singh B, Roy MK, Apirion D. Ribonuclease E is involved in the processing of 5S from a number of rRNA transcription units. Eur J Biochem 125:283-289, 1982.
- Singh B, Thornton GB, Roy J, Talib S, De BP, Banerjee AK. Frequent intragenic transcription termination within the N gene of vesicular stomatitis virus. Virology 122:239-250, 1982.
- Singh B, Apirion D. Primary and secondary structure in a precursor of 5S rRNA. Biochim Biophys Acta 698:252-259, 1982.
- Singh B, Biswas M, Datta A. Inducible N-acetylgluosamine binding protein in yeasts. J Bacteriol 114:1-6, 1980.
- Biswas M, Singh B, Datta A. Induction of N-acetylmannosamine catabolic pathway in yeast. Biochim Biophys Acta 585:535-542, 1979.
- Singh, B, Datta, A. Glucose repression of the inducible catabolic pathway for N-acteylglucosamine in yeast. Biochem Biophys Res Commun 84:58-64, 1978.
Other Articles
- Singh B, Sarli VN, Milligan RD, Kinne HE, Shamsnia A, Washburn LJ, Lucci A Sensitization of resistant cells with a BET bromodomain inhibitor in a cell culture model of deep intrinsic resistance in breast cancer (Preprint). Research Square, 2022.
Patient Reviews
CV information above last modified December 12, 2023